Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Cerus Corp (NQ: CERS )

6.130 USD +0.060 (+0.99%)
Official Closing Price Updated: 6:50 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Cerus Corp

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Cerus Corporation to Participate in Jefferies Virtual Global Plasma Summit
Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to... 
From Business Wire News Releases
Cerus Corporation Announces Record Fourth Quarter and Full Year 2020 Financial Results
Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2020. 
From Business Wire News Releases
Cerus Corporation and Shandong Zhongbaokang Medical Implements Partner to Establish Joint Venture in China
Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joint venture (JV) with the intent to develop, obtain regulatory... 
From Business Wire News Releases
Cerus Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 25, 2021, after the close of the stock market. The... 
From Business Wire News Releases
Cerus Corporation to Participate in Upcoming Virtual Investor Conferences
Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to... 
From Business Wire News Releases
Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2020 Product Revenue
Cerus Corporation (Nasdaq: CERS) announced today preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guidance. 
From Business Wire News Releases
Cerus’ Distribution Partner, CEI, Announces Three-Year Tender Award with the Minas Gerais Hematology and Hemotherapy Center Foundation (HemoMinas) in Brazil for the INTERCEPT Blood System for Platelet
Cerus Corporation (Nasdaq: CERS) today announced that its distribution partner, Companhia Energética Integrada (CEI), was awarded a three-year contract with the HemoMinas Foundation (“HemoMinas”) of... 
From Business Wire News Releases
Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting
Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute... 
From Business Wire News Releases
Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Cryoprecipitation
Cerus Corporation (Nasdaq: CERS) today announced that the US Food and Drug Administration (FDA) has granted approval of the INTERCEPT Blood System for Cryoprecipitation. The system is used to produce... 
From Business Wire News Releases
Cerus Corporation to Participate in Upcoming Virtual Investor Conferences
Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to... 
From Business Wire News Releases
Cerus Corporation Announces Record Third Quarter 2020 Results
Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2020. 
From Business Wire News Releases
Demand for Effective Diagnostics Surges Alongside a New Wave
- FinancialBuzz.com News Commentary 
From PR Newswire
Cerus Corporation to Release Third Quarter 2020 Financial Results on October 29, 2020
Cerus Corporation (Nasdaq:CERS) announced today that its third quarter 2020 financial results will be released on Thursday, October 29, 2020, after the close of the stock market. The Company will host... 
From Business Wire News Releases
Cerus Corporation Announces Five-Year FDA Contract for the Development of Next Generation Pathogen Reduction Technology to Treat Whole Blood
Cerus Corporation (Nasdaq:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of next-generation compounds to optimize... 
From Business Wire News Releases
The Evolution of Diagnostic Capabilities Underscores the Fight Against Viral Infections
FinancialBuzz.com News Commentary 
From PR Newswire
Cerus Corporation Announces Schedule of Presentations at the AABB 2020 Virtual Annual Meeting
Cerus Corporation (Nasdaq:CERS) announced today its lineup of abstract presentations at the AABB 2020 Virtual Annual Meeting, which will take place on October 3rd through October 5th. 
From Business Wire News Releases
New Challenges Spur Greater Innovation in Diagnostic Testing Capabilities
- FinancialBuzz.com News Commentary 
From PR Newswire
Cerus Corporation to Participate in Upcoming Virtual Investor Conferences
Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to... 
From Business Wire News Releases
Cerus INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch
Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch. 
From Business Wire News Releases
Cerus Corporation Announces Record Second Quarter 2020 Results
Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2020. 
From Business Wire News Releases
Cerus Corporation Announces a Five-Year Tender Award by the Hong Kong Red Cross Blood Transfusion Service for INTERCEPT Blood Systems
Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets. The Hong... 
From Business Wire News Releases
Cerus Corporation to Release Second Quarter 2020 Financial Results on August 4, 2020
Cerus Corporation (Nasdaq:CERS) announced today that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020, after the close of the stock market. The Company will host a... 
From Business Wire News Releases
Cerus Corporation Reports Successful Inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma
Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for... 
From Business Wire News Releases
Cerus Corporation Celebrates World Blood Donor Day
Cerus Corporation (Nasdaq:CERS) celebrates World Blood Donor Day this Sunday, June 14, 2020. Enacted by the World Health Organization (WHO), World Blood Donor Day highlights the need for safe blood and... 
From Business Wire News Releases
Cerus Corporation Announces FDA PMA Supplement Submission for Pathogen-Reduced Cryoprecipitated Fibrinogen Complex
Cerus Corporation (Nasdaq:CERS) announced today that the Company has submitted a pre-market approval supplement (PMA-S) to the FDA for a pathogen reduced cryoprecipitated fibrinogen complex with 5-day... 
From Business Wire News Releases
Cerus Corporation Announces First Quarter 2020 Results
Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2020. 
From Business Wire News Releases
Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Plasma with Alternate Plastic Disposable Kits
Cerus Corporation (Nasdaq:CERS) announced today FDA regulatory approval for manufacture of INTERCEPT plasma with a new, alternative plastic disposable kit. The planned conversion to these new kits is... 
From Business Wire News Releases
Cerus Corporation to Release First Quarter 2020 Financial Results on May 5, 2020
Cerus Corporation (Nasdaq:CERS) announced today that its first quarter 2020 financial results will be released on Tuesday, May 5, 2020, after the close of the stock market. The Company will host a... 
From Business Wire News Releases
Cerus Corporation Announces Expansion of BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells
Cerus Corporation (Nasdaq:CERS) today announced an amendment to the Company’s contract with the Biomedical Advanced Research and Development Authority (BARDA). The amendment provides an additional $14... 
From Business Wire News Releases
Cerus Corporation Provides Update on COVID-19 Related Activities
Cerus Corporation (Nasdaq:CERS) today announced the Company’s recent activities related to COVID-19 and efforts to ensure that patients have readily available access to pathogen-reduced blood... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.